With the worldwide acquisition from the Danish Leo Pharma of the four flagship products One-Alpha, Locoid, Pimafucin and Zineryt (whose cumulative turnover exceeded 110 million euros annually), Cheplapharm Arzneimittel inherits a drug that works very well in Morocco. This is One-Alpha which acts as a supplement to vitamin D and promotes bone fixation of calcium. Distributed until then by Polymedic, a pharmaceutical company acquired in 2019 by the Emirati NBK Capital, the distribution of this drug should probably switch to Bottu Maroc, a long-standing partner of the German group Cheplapharm Arzneimittel.
And the one which takes its name from the Cheplaren (diuretic) specialty the day after its creation 23 years ago, does not intend to stop there, since negotiations are underway with Sanofi for a potential deal to buy strictly assets. That is to say, the importance attached by the family-owned group based on the shores of the Baltic Sea to the Moroccan market, where it does not yet have direct subsidiaries. But that is likely to change soon, with the strategy of accelerating international development initiated in 2016 with a first direct establishment outside of Germany.
Recall that the Cheplapharm Arzneimittel group generated in 2020 a consolidated turnover of nearly 600 million euros (more than MAD 6.5 billion), against barely 3 million euros (MAD 33 million) in 2007 ! Thanks to a strategy of acquisitions of take-back drugs proven in their time and with a real patient base, the Cheplapharm Arzneimittel group has shown exponential growth over the past 15 years.